{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:14:58Z","timestamp":1760242498814,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T00:00:00Z","timestamp":1506124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Previously called Crow\u2013Fukase syndrome, POEMS syndrome is characterized by poly-neuropathy, osteo-sclerotic myeloma, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes. Extremely elevated levels of serum vascular endothelial growth factor (VEGF) are characteristic of the syndrome. Chronic hepatitis B (HBV) and C (HCV) infections can also be present in POEMS. The pathogenesis of the syndrome is not well understood. The link between chronic alcohol consumption and this malignant condition has not been reported until now. In addition, no previous study has evaluated the influence of cytokine and chemokines or viruses in the severity and evolution of POEMS. Objectives: (1) to describe a heavy-alcohol user, who was diagnosed with POEMS; (2) to demonstrate the utility of quantitative measurement of serum levels of VEGF in the diagnosis of POEMS and the monitoring of therapeutic interventions; (3) to demonstrate that overproduction of pro-inflammatory cytokines is a characteristic of POEMS. Methods: We describe a case of a POEMS patient presenting HCV and who is a heavy drinker; we compare the serum levels of cytokines and chemokines between the POEMS patient with 80 patients with HCV, 12 healthy controls, and 80 individuals with alcoholic liver disease (ALD). We quantified (ELISA pg\/mL) the levels of VEGF, Interferon gamma (IFN-\u03b3), Tumor Necrosis Factor alpha (TNF-\u03b1), Regulated-upon-Activation Normal-T-cell-Expressed and presumably-Secreted (RANTES), and Nuclear Factor kappa-B (NF\u03baB). Results: In POEMS patients, VEGF levels were elevated versus control or other diseases, TNF\u03b1 levels were higher versus control, but lower when compared with HCV or ALD patients. VEGF levels in POEMS patients decreased with therapeutic intervention. Conclusions: Chronic alcohol misuse can be a strong risk factor to rare malignancies such as POEMS syndrome. Extreme elevation of VEGF levels is diagnostic for POEMS syndrome, and should be followed to assess response to therapy. In addition, other comorbidities should be considered individually to ensure personalized therapeutic intervention.<\/jats:p>","DOI":"10.3390\/cancers9100129","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T04:28:01Z","timestamp":1506400081000},"page":"129","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Alcohol Misuse Link to POEMS Syndrome in a Patient"],"prefix":"10.3390","volume":"9","author":[{"given":"John","family":"Neary","sequence":"first","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Juravinski Hospital, Hamilton, ON L8N 3Z5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Sunnybrook Health Sciences Centre and Department of Internal Medicine, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Neuman","sequence":"additional","affiliation":[{"name":"In Vitro Drug Safety and Biotechnology, Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5G 1L5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ana.410300111","article-title":"Neuropathy associated with monoclonal gammopathies of undetermined significance","volume":"30","author":"Gosselin","year":"1991","journal-title":"Ann. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Joint Task Force of the EFNS and the PNS (2010). European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J. Peripher. Nerv. Syst., 15, 185.","DOI":"10.1111\/j.1529-8027.2010.00278.x"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/(SICI)1097-4598(199908)22:8<1030::AID-MUS4>3.0.CO;2-H","article-title":"Anti-MAG IgM-penetration into myelinated fibers correlates with the extent of myelin widening","volume":"22","author":"Ritz","year":"1999","journal-title":"Muscle Nerve"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/NEN.0b013e3181fa44af","article-title":"Morphological progression of myelin abnormalities in IgM-monoclonal gammopathy of undetermined significance anti-myelin-associated glycoprotein neuropathy","volume":"69","author":"Kawagashira","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/ajh.24802","article-title":"POEMS syndrome: 2017 update on diagnosis, risk stratifications, and management","volume":"92","author":"Dispenzieri","year":"2017","journal-title":"Am. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/(SICI)1097-4598(199811)21:11<1390::AID-MUS5>3.0.CO;2-4","article-title":"Overproduction of vascular endothelial growth factor\/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome","volume":"21","author":"Watanabe","year":"1998","journal-title":"Muscle Nerve"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1517\/14656566.6.6.945","article-title":"Treatment options for POEMS syndrome","volume":"6","author":"Dispenzieri","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11864-004-0016-4","article-title":"Treatment of POEMS syndrome","volume":"5","author":"Dispenzieri","year":"2004","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jnnp.63.3.385","article-title":"Long term melphalan-prednisolone chemotherapy for POEMS syndrome","volume":"63","author":"Kuwabara","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1600-0609.2008.01037.x","article-title":"Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome","volume":"80","author":"Dispenzieri","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.blre.2007.07.004","article-title":"POEMS syndrome","volume":"21","author":"Dispenzieri","year":"2007","journal-title":"Blood Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1212\/01.wnl.0000323811.42080.a4","article-title":"Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome","volume":"71","author":"Kuwabara","year":"2008","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1378\/chest.07-1800","article-title":"Pulmonary manifestations in patients with POEMS syndrome: A retrospective review of 137 patients","volume":"133","author":"Allam","year":"2008","journal-title":"Chest"},{"key":"ref_14","first-page":"Cd006828","article-title":"Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome","volume":"6","author":"Kuwabara","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ajh.23644","article-title":"POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Dispenzieri","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/1097-4598(200007)23:7<1051::AID-MUS7>3.0.CO;2-V","article-title":"Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome","volume":"23","author":"Hashiguchi","year":"2000","journal-title":"Muscle Nerve"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Warsame, R., Yanamandra, U., and Kapoor, P. (2017). POEMS Syndrome: An Enigma. Curr. Hematol. Malig. Rep.","DOI":"10.1007\/s11899-017-0367-0"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.24171","article-title":"POEMS syndrome: Update on diagnosis, risk-stratification, and management","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.V81.9.2452.2452","article-title":"Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support","volume":"81","author":"Rabinowitz","year":"1993","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1620\/tjem.210.269","article-title":"Recurrent Crow-Fukase syndrome associated with increased serum levels of vascular endothelial growth factor: A case report and review of the literature","volume":"210","author":"Mineta","year":"2006","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1212\/01.wnl.0000344569.13496.ff","article-title":"Serum VEGF levels in POEMS syndrome and in immunemediated neuropathies","volume":"72","author":"Terenghi","year":"2009","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3816\/CLM.2006.n.043","article-title":"Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support","volume":"7","author":"Kastritis","year":"2006","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood-2007-03-082354","article-title":"Lenalidomide therapy in a patient with POEMS syndrome","volume":"110","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.bmt.1703600","article-title":"Successful use of autologous bone marrow transplantation in treating a patient with POEMS syndrome","volume":"30","author":"Soubrier","year":"2002","journal-title":"Bone Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bmt.2016.214","article-title":"The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents","volume":"52","author":"Chakraborty","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1182\/blood.V99.8.3057","article-title":"High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome","volume":"99","author":"Jaccard","year":"2002","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.20280","article-title":"Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome","volume":"79","author":"Ganti","year":"2005","journal-title":"Am. J. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/9\/10\/129\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:45:46Z","timestamp":1760208346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/9\/10\/129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,23]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10]]}},"alternative-id":["cancers9100129"],"URL":"https:\/\/doi.org\/10.3390\/cancers9100129","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2017,9,23]]}}}